CAMBRIDGE, England, October 9, 2013 /PRNewswire/ --
Kymab, a monoclonal antibody biopharmaceutical company, announces today it has notified the English Court that it will defend the UK patent proceedings brought by Regeneron in respect of European patent EP1360287.
Regeneron initiated these proceedings in September 2013. Kymab will defend the UK patent action on the grounds of non-infringement and invalidity of the patent.
Earlier, in June 2013, Kymab opposed the equivalent Regeneron European patent in the European Patent Office. The opposition proceedings are pending.
Kymab is confident of success in both the European Patent Office and the English Court.
About Kymab
Kymab is a biopharmaceutical company focused on the discovery and development of fully human monoclonal antibody drugs using its proprietary Kymouse™ transgenic antibody platform.
Kymouse™ has been designed to maximise the diversity of human antibodies produced in response to immunisation with antigens. Selecting from a broad diversity of fully human antibodies assures the highest probability of finding that rare drug candidate with best-in-class characteristics. Kymab is using the platform for its internal drug discovery programmes and in partnership with pharmaceutical companies. The first Kymouse™ antibody discovery agreement was concluded with Novo Nordisk in 2013.
Founded in 2009, Kymab raised £20m of equity financing in 2010 from the investment division of the Wellcome Trust. It has an experienced management team with a successful track record in drug discovery and development and has six current therapeutic antibody discovery programmes in oncology, inflammatory and vascular diseases.
For further information, please visit http://www.kymab.com
Contact Kymab:
Dr. Christian Grøndahl, Chief Executive Officer
Tel: +44(0)1223-833301, Email: [email protected]
Hume Brophy:
Mary Clark, Hollie Vile, Supriya Mathur
Tel: +44(0)20-3440-5654, Email: [email protected]
Kymab and Kymouse are trademarks of Kymab Limited.
SOURCE Kymab
Share this article